Department of Dermatology & Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.
City Medical Aesthetics Center, Vancouver, British Columbia, Canada.
Dermatol Surg. 2021 Nov 1;47(11):1466-1472. doi: 10.1097/DSS.0000000000003159.
Beyond submental fat reduction, injectable deoxycholic acid (DCA) has gained popularity in recent years for various minimally invasive lipolysis applications.
To summarize and evaluate the evidence of off-label uses of injectable DCA.
MEDLINE, Embase, CINAHL, Web of Science, and CENTRAL were searched. The outcomes measured included applications of DCA, treatment regimen, and its efficacy. An overall success rate for each condition was calculated based on the improvement defined in the included studies.
Eleven studies evaluated the cosmetic use of DCA for excess adipose tissue on various anatomical locations. The outcomes were evaluated at time points ranging from 1 to 21 months post-treatment, with overall success rates over 85%. Eight case reports and series reported the success of using DCA treating lipomas, xanthelasmas, paradoxical adipose hyperplasia, fibrofatty residue of infantile hemangioma, piezogenic pedal papules, and HIV-associated lipohypertrophy. Although the preliminary efficacies were high, the overall recommendations for off-label uses are weak because of the lack of high-level studies.
The review emphasizes the diversity of injectable DCA as a minimally invasive technique for lipolysis. Further high-level studies demonstrating consistent treatment regimens and methods of evaluation are warranted to make more definitive recommendations regarding off-label DCA use.
除了颏下脂肪减少外，近年来，注射用脱氧胆酸（DCA）因其在各种微创脂肪分解应用中的广泛应用而受到关注。
总结和评估注射用 DCA 的非适应证用途的证据。
检索 MEDLINE、Embase、CINAHL、Web of Science 和 CENTRAL。测量的结果包括 DCA 的应用、治疗方案及其疗效。根据纳入研究中定义的改善情况，计算每种情况下的总体成功率。
11 项研究评估了 DCA 在各种解剖部位用于多余脂肪组织的美容用途。治疗后 1 至 21 个月的时间点评估了结果，总体成功率超过 85%。8 例病例报告和系列报告了使用 DCA 治疗脂肪瘤、黄瘤、反常脂肪增生、婴儿血管瘤纤维脂肪残留、压电足底丘疹和 HIV 相关脂肪营养不良的成功案例。尽管初步疗效较高，但由于缺乏高水平研究，对非适应证用途的总体建议较弱。
该综述强调了注射用 DCA 作为一种微创脂肪分解技术的多样性。需要进一步的高水平研究来证明一致的治疗方案和评估方法，以便对 DCA 的非适应证用途做出更明确的建议。
